{"organizations": [], "uuid": "8a94a38807a416ead12b61ff7c4c74162b3e8a97", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/4", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/05/01/globe-newswire-loxo-oncology-to-announce-first-quarter-2018-financial-results.html", "country": "US", "domain_rank": 767, "title": "Loxo Oncology to Announce First Quarter 2018 Financial Results", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.001, "site_type": "news", "published": "2018-05-01T14:45:00.000+03:00", "replies_count": 0, "uuid": "8a94a38807a416ead12b61ff7c4c74162b3e8a97"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/05/01/globe-newswire-loxo-oncology-to-announce-first-quarter-2018-financial-results.html", "ord_in_thread": 0, "title": "Loxo Oncology to Announce First Quarter 2018 Financial Results", "locations": [], "entities": {"persons": [], "locations": [{"name": "conn.", "sentiment": "none"}, {"name": "stamford", "sentiment": "none"}], "organizations": [{"name": "loxo oncology, inc.", "sentiment": "neutral"}, {"name": "loxo oncology", "sentiment": "none"}, {"name": "loxo oncology loxo oncology", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "STAMFORD, Conn., May 01, 2018 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, will announce financial results for the first quarter ended March 31, 2018 on May 8, 2018 before the Nasdaq market open. At 8:00 a.m. ET that day, Loxo Oncology management will host a conference call to discuss these financial results, in addition to recent updates on development and corporate activities.\nTo participate in the conference call, please dial (877) 930-8065 (domestic) or (253) 336-8041 (international) and refer to conference ID 1979239. A replay will be available shortly after the conclusion of the call and archived on the company's website for 30 days following the call.\nAbout Loxo Oncology\nLoxo Oncology is a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers. Our pipeline focuses on cancers that are uniquely dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect. We believe that the most selective, purpose-built medicines have the highest probability of maximally inhibiting the intended target, thereby delivering best-in-class disease control and safety. Our management team seeks out experienced industry partners, world-class scientific advisors and innovative clinical-regulatory approaches to deliver new cancer therapies to patients as quickly and efficiently as possible. For more information, please visit the company's website at www.loxooncology.com .\nContacts for Loxo Oncology, Inc.\nCompany:\nLauren Cohen\nDirector, Corporate Communications\nlcohen@loxooncology.com\nInvestors:\nPeter Rahmer\nEndurance Advisors, LLC\n415-515-9763\nprahmer@enduranceadvisors.com\nMedia:\nDan Budwick\n1AB Media\n973-271-6085\ndan@1abmedia.com\nSource:Loxo Oncology, Inc.", "external_links": ["https://www.globenewswire.com/NewsRoom/AttachmentNg/dc8fa945-1154-4107-b556-4a4caf6bf563", "https://www.globenewswire.com/Tracker?data=6v8GdJvLG_D1RMjU11zKwme7u6JZ6h6HC2KFUK64AAf_ePOA8DOiy_f5EOrvT_JFKyG9ulyhMktP_ZLqHhoO1nhhIc_h2FS7_9_YccVmTgE=", "https://www.globenewswire.com/Tracker?data=9rLm0B_kf3UUU2vYYRR2VKCmEU2TrYYMlWhoIa-ietwkQuvL6de0CeKj0aOKbNoovx9tWXnGMa_g4F922ol_gbsia2HOXaNAcwF7Y0-yDhdi8saikWaq4ECNfOpmoaygT1Z1Y45_Gkcrufvms3y1_9QLKsh4s_8tsGvUn1KyoRZXIL_4FkbgiKZzqoKCRVjZcqz0Y2v92eV4aJGZENRqksCXHdgpJfSUOAiwxni7w7rw4TIPYJ_0GpWH7XBq24lKC4bS-dA8nYo0pUF3a2-UCw==", "https://www.globenewswire.com/Tracker?data=jpoOOVtRtGGIq3uETedBeVCDMttzHJTon5_esSVuqNglhgbmacSF8ycFiYtPILvk-5tFMnvaMFbXo_CQNdm0LQ==", "https://www.globenewswire.com/Tracker?data=OaFagIu0Eq8nmVvWZ1j5EN-I5wOfiBPgOTF5uFRsjSpG9amZkf5iEQ9j7Y7uZNf7XEv_be-1QSJHxb8t8uXkb67Atp0ht_sO3M0gFxK-aBpuUNjhLiQhTts8bYbsbXX9", "https://www.globenewswire.com/Tracker?data=BUktq1EP63GseZBaKR7_Nhst4JTviLu3_YcGdy2l0JK8QFEEUYbea_cf0Vl16Ozuzh-AKJ4pH6IP7Wh3zdpsnnxToduwD_Ok7ec68vdNt4Q="], "published": "2018-05-01T14:45:00.000+03:00", "crawled": "2018-05-01T15:41:00.004+03:00", "highlightTitle": ""}